The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer

The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer

Recombinant human erythropoietin (Epo) is an effective and convenient treatment for cancer-related anaemia. In our study for the first time, we evaluated the effect of simultaneous use of Epo and Bruton’s tyrosine kinase (BTK) inhibitor LFM-A13 on the viability and tumour development of breast cance...

Full description

Bibliographic Details
Main Authors: Dariusz Rozkiewicz, Justyna Magdalena Hermanowicz, Anna Tankiewicz-Kwedlo, Beata Sieklucka, Krystyna Pawlak, Robert Czarnomysy, Krzysztof Bielawski, Arkadiusz Surazynski, Joanna Kalafut, Alicja Przybyszewska, Mariusz Koda, Katarzyna Jakubowska, Adolfo Rivero-Muller, Dariusz Pawlak
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:Journal of Enzyme Inhibition and Medicinal Chemistry
Subjects:
erythropoietin
lfm-a13
bruton’s tyrosine kinase
breast cancer
zebrafish
Online Access:http://dx.doi.org/10.1080/14756366.2020.1818738

Internet

http://dx.doi.org/10.1080/14756366.2020.1818738

Similar Items